December 10th 2020
In our exclusive interview, Aditya Bardia, MD, MPH, sheds light on the considerations that should be made leading up to treatment selection in common clinical scenarios in breast cancer.
December 7th 2020
In our exclusive interview, Caroline Robert, MD, PhD, discusses her groundbreaking work on clinical trials evaluating anti–CTLA-4 and anti–PD-1 antibodies in advanced melanoma, her experiences as a researcher in France and the United States, her love of traveling, and next steps for the field.
December 3rd 2020
In our exclusive interview, Dr. Huntsman discusses the elements of precision medicine that have contributed to its growth in the field of oncology, some of the setbacks regarding its integration, and areas of research that have the potential to propel precision medicine to the next tier of scientific discovery and application.
November 30th 2020
In our exclusive interview, Dr. Karlan discusses pivotal moments in her career as a gynecologic oncologist, the challenges of forging a name for herself, and future directions for the field.
November 26th 2020
In our exclusive interview, Dr. Loaiza-Bonilla explains how AI can be used to optimize patient care, provides insight into the research that has been done to develop potential applications for AI in oncology, and sheds light on some of the barriers that have to be overcome in order to effectively implement AI in oncology.
November 23rd 2020
In our exclusive interview, Dr. Oxnard explained how precision medicine has affected the treatment landscape of lung cancer, discussed the current capabilities of liquid biopsy, and forecasted the future of precision oncology in the field.
November 19th 2020
In our exclusive interview, Dr. Mesa and Dr. Ulmer discuss the current roles of ruxolitinib and fedratinib in myelofibrosis, current guidance for JAK inhibitor dosing, the utility of re-exposure to JAK inhibitors, and clinical trial options.
November 16th 2020
In our exclusive interview, Dr. Raez discusses the reasons for the declines in routine screening and referrals due to the coronavirus disease 2019, anticipated consequences, and some of the ways in which the health care community can combat these newfound challenges.
November 12th 2020
In our exclusive interview, Nabil F. Saba, MD, FACP, sheds light on the implications of targeting HRAS in head and neck squamous cell carcinoma, details the data that has been reported to date with tipifarnib, and shares his expectations for the ongoing KO-TIP-007 trial.
November 9th 2020
In our exclusive interview, Dr. Aggarwal and Dr. Gandara discuss the evolution of liquid biopsy in lung cancer, explain the clinical implications of recent liquid biopsy approvals, and forecast the future of liquid biopsy in the field.
End of data